PT-141 — reference
Melanocortin agonist. FDA-approved (Vyleesi) for acquired, generalized HSDD in premenopausal women.
Regulatory status
FDA-Approved (labeled use). FDA-approved for its labeled indication and population only. Off-label use (incl. in men) is not FDA-approved; community-reported doses for that use are often lower (~0.5–1 mg).
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~2.7 hours. FDA label (Vyleesi/bremelanotide).
This figure is tagged FDA label in our evidence system. This figure appears in an approved product's prescribing information, which is the strongest tier in our system — a regulator-reviewed number for a specific approved product. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is PT-141 FDA-approved?
What is the half-life of PT-141?
How reliable is that half-life figure?
What cautions are associated with PT-141?
Does Peptide Plug publish dosing for PT-141?
Does Peptide Plug sell PT-141?
Related tools
Free, no account required.